These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1447395)

  • 21. Drug regulation in the United States and the United Kingdom: the Depo-Provera story.
    Richard BW; Lasagna L
    Ann Intern Med; 1987 Jun; 106(6):886-91. PubMed ID: 2953290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is more neonatal intensive care always better? Insights from a cross-national comparison of reproductive care.
    Thompson LA; Goodman DC; Little GA
    Pediatrics; 2002 Jun; 109(6):1036-43. PubMed ID: 12042540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: a hypothesis-generating study.
    Lexchin J
    Ann Pharmacother; 2006 Dec; 40(12):2216-22. PubMed ID: 17132811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Canada signs agreements to potentially share drug information with the US and Australia.
    Blouin D
    CMAJ; 2004 Jul; 171(2):121. PubMed ID: 15262871
    [No Abstract]   [Full Text] [Related]  

  • 26. Dioxin-like activities, halogenated flame retardants, organophosphate esters and chlorinated paraffins in dust from Australia, the United Kingdom, Canada, Sweden and China.
    Wong F; Suzuki G; Michinaka C; Yuan B; Takigami H; de Wit CA
    Chemosphere; 2017 Feb; 168():1248-1256. PubMed ID: 27814953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. International comparison of waiting times for selected cardiovascular procedures.
    Carroll RJ; Horn SD; Soderfeldt B; James BC; Malmberg L
    J Am Coll Cardiol; 1995 Mar; 25(3):557-63. PubMed ID: 7860896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The rate of development of new drugs in the United States, 1963 through 1975.
    Wardell WM; Hassar M; Anavekar SN; Lasagna L
    Clin Pharmacol Ther; 1978 Aug; 24(2):133-45. PubMed ID: 679593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulatory review intervals for ophthalmic new drug applications at the US Food and Drug Administration.
    Novack GD
    Am J Ophthalmol; 1998 Jul; 126(1):122-6. PubMed ID: 9683158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Time to Entry for New Cancer Medicines: From European Union-Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden.
    Ferrario A
    Value Health; 2018 Jul; 21(7):809-821. PubMed ID: 30005753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The costs and benefits of regulations for reimbursement of new drugs.
    Lundkvist J; Jönsson B; Rehnberg C
    Health Policy; 2006 Dec; 79(2-3):337-44. PubMed ID: 16549221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. International variation in ethics and contract approval processes for a low-risk observational study of mechanical ventilation discontinuation practices.
    Rizvi L; Griffin K; Zytaruk N; Cook DJ; Sykes J; Burns KEA
    J Clin Epidemiol; 2023 Dec; 164():27-34. PubMed ID: 37858776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of numbers and timing of new medication regulatory approvals in Canada and New Zealand.
    Rawson NSB
    Regul Toxicol Pharmacol; 2019 Feb; 101():24-28. PubMed ID: 30391284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.
    DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
    Pharmacoeconomics; 1995 Feb; 7(2):152-69. PubMed ID: 10155302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK.
    Pritchard C; Hickish T
    Lancet; 2011 Apr; 377(9772):1149; author reply 1149-50. PubMed ID: 21459201
    [No Abstract]   [Full Text] [Related]  

  • 36. Factors associated with antiretroviral treatment uptake and adherence: a review. Perspectives from Australia, Canada, and the United Kingdom.
    Bolsewicz K; Debattista J; Vallely A; Whittaker A; Fitzgerald L
    AIDS Care; 2015; 27(12):1429-38. PubMed ID: 26641139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
    Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
    JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy.
    Abraham J; Davis C
    Soc Sci Med; 2005 Sep; 61(5):881-92. PubMed ID: 15955393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Publication rates in Australia, Canada, UK, and US pharmacy schools.
    Thompson DF; Patatanian LK; Mathys ML
    Ann Pharmacother; 2001 Jan; 35(1):126-7. PubMed ID: 11197576
    [No Abstract]   [Full Text] [Related]  

  • 40. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.